Daniel Gorovets

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7025658/publications.pdf

Version: 2024-02-01

59 papers	1,855 citations	304743 22 h-index	276875 41 g-index
59 all docs	59 docs citations	59 times ranked	3081 citing authors

#	Article	IF	Citations
1	Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion. European Urology Oncology, 2023, 6, 275-281.	5.4	6
2	Racial inequity and other social disparities in the diagnosis and management of bladder cancer. Cancer Medicine, 2023, 12, 640-650.	2.8	6
3	Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report. Journal of Immunotherapy and Precision Oncology, 2022, , .	1.4	0
4	Urinary Outcomes for Men With High Baseline International Prostate Symptom Scores Treated With Prostate SBRT. Advances in Radiation Oncology, 2021, 6, 100582.	1.2	3
5	Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?. Clinical and Translational Radiation Oncology, 2021, 26, 47-54.	1.7	4
6	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 30-37.	1.6	239
7	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	6.3	98
8	Clinical implementation of deep learning contour autosegmentation for prostate radiotherapy. Radiotherapy and Oncology, 2021, 159, 1-7.	0.6	56
9	Quantifying clinical severity of physics errors in high-dose rate prostate brachytherapy using simulations. Brachytherapy, 2021, 20, 1062-1069.	0.5	3
10	Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy. Radiotherapy and Oncology, 2021, 159, 33-38.	0.6	18
11	TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology, 2021, 5, 1259-1269.	3.0	10
12	Sildenafil Citrate and Risk of Biochemical Recurrence in Prostate Cancer Patients Treated with Radiation Therapy: Post-Hoc Analysis of a Randomized Controlled Trial. Journal of Sexual Medicine, 2021, 18, 1467-1472.	0.6	4
13	Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity. BJU International, 2021, , .	2.5	1
14	Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer. Brachytherapy, 2021, 20, 1099-1106.	0.5	3
15	A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 101-109.	0.8	19
16	Current considerations for radiotherapy in HPVâ€associated head and neck cancer. Journal of Surgical Oncology, 2021, 124, 945-951.	1.7	3
17	Patterns of Radiotherapy Use and Outcomes in Head and Neck Softâ€Tissue Sarcoma in a National Cohort. Laryngoscope, 2020, 130, 120-127.	2.0	5
18	Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer, 2020, 126, 444-452.	4.1	38

#	Article	IF	Citations
19	Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer. European Urology Oncology, 2020, 3, 748-755.	5.4	25
20	Financial toxicity associated with treatment of localized prostate cancer. Nature Reviews Urology, 2020, 17, 28-40.	3.8	44
21	Prostate SBRT With Intrafraction Motion Management Using a Novel Linear Acceleratorâ€"Based MV-kV Imaging Method. Practical Radiation Oncology, 2020, 10, e388-e396.	2.1	14
22	Strict bladder filling and rectal emptying during prostate SBRT: Does it make a dosimetric or clinical difference?. Radiation Oncology, 2020, 15, 239.	2.7	10
23	Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 1213-1224.	1.2	7
24	Prognostic significance of human papillomavirus and <scp>Epsteinâ€Bar</scp> virus in nasopharyngeal carcinoma. Head and Neck, 2020, 42, 2364-2374.	2.0	12
25	Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies. Clinical and Translational Radiation Oncology, 2020, 23, 30-34.	1.7	2
26	Treating the SARSâ€CoVâ€2â€"positive patient with cancer: A proposal for a pragmatic and transparent ethical process. Cancer, 2020, 126, 3896-3899.	4.1	5
27	Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, 905-913.	0.8	12
28	Salvage surgery for recurrent larynx cancer. Head and Neck, 2019, 41, 3906-3915.	2.0	22
29	Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. Head and Neck, 2019, 41, 3551-3563.	2.0	16
30	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. British Journal of Cancer, 2019, 121, 897-903.	6.4	32
31	Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy. Radiotherapy and Oncology, 2019, 140, 34-40.	0.6	2
32	Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 42-49.	0.8	93
33	Organ preservation for patients with anterior mucosal squamous cell carcinoma of the nasal cavity: Rhinectomyâ€free survival in those refusing surgery. Head and Neck, 2019, 41, 2741-2747.	2.0	11
34	Comparison of Motion-Insensitive T2-Weighted MRI Pulse Sequences for Visualization of the Prostatic Urethra During MR Simulation. Practical Radiation Oncology, 2019, 9, e534-e540.	2.1	14
35	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. Journal of Surgical Oncology, 2019, 119, 130-142.	1.7	40
36	Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature. Head and Neck, 2019, 41, 1418-1426.	2.0	21

#	Article	IF	Citations
37	Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer. Journal of Urology, 2019, 201, 1127-1133.	0.4	15
38	Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). International Journal of Particle Therapy, 2019, 5, 1-10.	1.8	10
39	Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncology, 2018, 78, 94-101.	1.5	40
40	Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103. Brachytherapy, 2018, 17, 251-258.	0.5	36
41	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Familial Cancer, 2018, 17, 71-77.	1.9	10
42	Proton Therapy for Head and Neck Cancer. Current Treatment Options in Oncology, 2018, 19, 28.	3.0	46
43	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. Thyroid, 2018, 28, 1180-1189.	4.5	23
44	Magnetic resonance imaging-based salvage brachytherapy: Moving toward a focal paradigm. Brachytherapy, 2017, 16, 770-777.	0.5	7
45	Unification of favourable intermediateâ€, unfavourable intermediateâ€, and very highâ€risk stratification criteria for prostate cancer. BJU International, 2017, 120, E87-E95.	2.5	34
46	Proton therapy for head and neck cancer: expanding the therapeutic window. Lancet Oncology, The, 2017, 18, e254-e265.	10.7	106
47	Real-time intraoperative evaluation of implant quality and dose correction during prostate brachytherapy consistently improves target coverage using a novel image fusion and optimization program. Practical Radiation Oncology, 2017, 7, 319-324.	2.1	11
48	Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy, 2017, 16, 1091-1098.	0.5	65
49	Sparing of high retropharyngeal nodal basins in patients with unilateral oropharyngeal carcinoma treated with intensity modulated radiation therapy. Practical Radiation Oncology, 2017, 7, 254-259.	2.1	17
50	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. Laryngoscope, 2017, 127, 377-382.	2.0	16
51	Patterns of regional and distant metastasis in esthesioneuroblastoma. Laryngoscope, 2016, 126, 1556-1561.	2.0	57
52	Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. Head and Neck, 2016, 38, E1285-93.	2.0	17
53	Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT. Oral Oncology, 2016, 58, 27-31.	1.5	8
54	Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?. Radiotherapy and Oncology, 2016, 121, 109-112.	0.6	3

#	Article	IF	Citations
55	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirusâ€“Related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 9-17.	0.8	121
56	Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancerâ€specific mortality and treatmentâ€related toxicity. BJU International, 2015, 116, 596-603.	2.5	46
57	Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. Journal of Urology, 2015, 194, 1624-1630.	0.4	93
58	Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience. Oral Oncology, 2015, 51, 709-715.	1.5	29
59	The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy. European Urology, 2015, 67, 1009-1016.	1.9	147